GlassScriptPhysician profile
Marc Zitin
NPI 1548237423
$15,890.34
in general payments reported to CMS, 2019-2025
40 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,575 · 2020: $1,250 · 2021: $2,041 · 2022: $2,397 · 2023: $2,470 · 2024: $2,218 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,547 · Education: $79.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,546.81 |
| Education | $79.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,056.04 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $2,837.61 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,493.12 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,431.84 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $521.73 | 2019-2025 | |
| Celgene Corporation | $451.88 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $343.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $328.05 | 2022-2025 | Dupixent |
| Genzyme Corporation | $277.29 | 2022-2025 | |
| Qol Medical, LLC | $259.32 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $233.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $224.20 | 2019-2023 | Rebyota |
| Lilly USA, LLC | $212.11 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $211.49 | 2019-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $194.06 | 2019-2024 | Dificid |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Zitin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.